Layton M J, Lock P, Metcalf D, Nicola N A
Walter and Eliza Hall Institute for Medical Research, Royal Melbourne Hospital, Parkville, Victoria, Australia.
J Biol Chem. 1994 Jun 24;269(25):17048-55.
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine whose activities appear to be mediated through a single heterodimeric receptor complex. Human LIF (hLIF) can bind to and activate mouse LIF (mLIF) receptors but mLIF is unable to bind to hLIF receptors. Cross-species competition of mLIF and hLIF for binding to the mLIF receptor was found to be dependent on which ligand was used as the radioactive tracer (Layton, M. J., Cross, B. A., Metcalf, D., Ward, L. D., Simpson, R. J., and Nicola, N. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8616-8620), and this phenomenon was investigated in the present study. We found that hLIF bound to the low affinity mLIF receptor with a 100-500-fold higher primary affinity and lower kinetic dissociation rate than mLIF, but both ligands displayed a single rate of ligand dissociation. In contrast, the binding of hLIF to low and high affinity hLIF receptors revealed two classes of binding site. The observed tracer-dependent phenomena suggested that both mLIF and hLIF interfere with the binding of each other to the mLIF receptor. A model is presented in which hLIF binds to two sites on mLIF and hLIF receptors, one of which interferes with the common site for mLIF. This model may reconcile some of the observed complexities of LIF/LIF receptor interactions.
白血病抑制因子(LIF)是一种多效性细胞因子,其活性似乎是通过单一的异二聚体受体复合物介导的。人LIF(hLIF)能与小鼠LIF(mLIF)受体结合并激活该受体,但mLIF无法与hLIF受体结合。已发现mLIF和hLIF对mLIF受体结合的种间竞争取决于用作放射性示踪剂的是哪种配体(莱顿,M. J.,克罗斯,B. A.,梅特卡夫,D.,沃德,L. D.,辛普森,R. J.,以及尼古拉,N. A.(1992年)《美国国家科学院院刊》89卷,8616 - 8620页),本研究对这一现象进行了调查。我们发现,hLIF与低亲和力的mLIF受体结合时,其初始亲和力比mLIF高100 - 500倍,动力学解离速率比mLIF低,但两种配体都表现出单一的配体解离速率。相比之下,hLIF与低亲和力和高亲和力的hLIF受体结合显示出两类结合位点。观察到的示踪剂依赖性现象表明,mLIF和hLIF都干扰彼此与mLIF受体的结合。本文提出了一个模型,其中hLIF与mLIF和hLIF受体上的两个位点结合,其中一个位点会干扰mLIF的共同结合位点。该模型可能有助于解释所观察到的LIF/LIF受体相互作用的一些复杂性。